Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjunctive Melatonin Gel With Minimally Invasive Non-Surgical Therapy (MINST) on Gingival Crevicular Fluid Galectin-3 and IL-1 in Stage III-IV Periodontitis: A Randomized Controlled Trial.

NCT07926282 is registered in ClinicalTrials.gov with Badr University as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07926282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Adjunctive Melatonin Gel With Minimally Invasive Non-Surgical Therapy (MINST) on Gingival Crevicular Fluid Galectin-3 and IL-1 in Stage III-IV Periodontitis: A Randomized Controlled Trial.
Lead sponsor
Badr University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
April 30, 2027
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

periodontitis, periodontitis (stage 3), periodontitis stage iv

Arms

As registered; 2 arms.

  • MINST + Melatonin Gel ExperimentalMelatonin gel, Minimally Invasive Non-Surgical Therapy (MINST)

    Patients with Stage III-IV periodontitis will receive minimally invasive non-surgical periodontal therapy (MINST) followed by intra-pocket application of melatonin gel once weekly for 4 weeks

  • MINST Alone Active comparatorMinimally Invasive Non-Surgical Therapy (MINST)

    Patients with Stage III-IV periodontitis will receive minimally invasive non-surgical periodontal therapy (MINST) only.

Primary endpoints

Registered primary outcome measures; 8 primary.

  • Clinical Attachment Level (CAL) Baseline, 1 month, and 2 months after treatment

    CAL will be measured in millimeters from the cemento-enamel junction to the base of the periodontal pocket using a UNC-15 periodontal probe at six sites per tooth.

  • Probing Pocket Depth (PPD) Baseline, 1 month, and 2 months after treatment

    PPD will be measured in millimeters from the gingival margin to the base of the periodontal pocket using a UNC-15 periodontal probe at six sites per tooth.

  • Full-Mouth Plaque Score (FMPS) Baseline, 1 month, and 2 months after treatment

    Percentage of tooth surfaces with plaque, recorded at four sites per tooth.

  • Full-Mouth Bleeding Score (FMBS) Baseline, 1 month, and 2 months after treatment

    Percentage of sites with bleeding on probing, recorded at six sites per tooth.

  • Gingival Recession (GR) Baseline, 1 month, and 2 months after treatment

    Measured in millimeters from the cemento-enamel junction to the gingival margin using a UNC-15 periodontal probe.

+3 more primary endpoints

Lead sponsor's other trials

Badr University, most recent start first.

Similar trials

Same condition (Periodontitis) and phase, most recent start first.